AstraZeneca, Allergan Sign Another Antibiotic Pact
This article was originally published in Scrip
Executive Summary
Allergan Inc. and AstraZeneca plc will join forces to further develop and commercialize ATM-AVI, a fixed-dose antibiotic for the treatment of infections caused by metallo β-lactamase (MBL)-producing Gram-negative pathogens – bacteria for which there are few viable antibiotics.
You may also be interested in...
Keeping Track Of Review Designations: BTDs For X4, F2G, And BMS; Another QIDP For Allergan
The latest news about products accepted into US FDA expedited review programs.
AZ's Zavicefta Gains EU Positive Opinion For “Superbug” Infections
The CHMP followed recent EMA guidance to take a flexible approach to drugs against multi-resistant pathogens when recommending approval for AstraZeneca’s latest antibacterial Zavicefta.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.